Request Info


Ask for our annual reports or more information
Email Us

Email Alerts

Sign up for email alerts
Email Alerts
Investor Relations

Investor Overview

 

Meridian is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company’s shares are traded through NASDAQ’s Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.

Stock Information
Stock chart for: VIVO
VIVO (Common Stock)
Price$17.86Change - 0.29
% Change 1.60%
Today's Open$18.17Intraday High$18.47
Previous Close$18.15Intraday Low$17.51
52 Week High$27.3752 Week High Date07/20/11
52 Week Low$14.8152 Week Low Date10/04/11
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.

Recent News
1/25/2012
Meridian Bioscience Reports First Quarter 2012 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2012 Guidance
Read full article
1/18/2012
Bioline Introduces HyperPAGE II Broad Range Prestained Protein Marker
Read full article
12/27/2011
Meridian Bioscience Receives FDA Clearance For ImmunoCard(R) C. difficile GDH Test
Read full article

View More »
Events and Presentations
View upcoming events as well as all archived events and presentations.
More »
Annual Meetings
View information about annual meetings, including reports and proxy statements
More »